TAG HIV Basic Science, Vaccines, and Cure Project Blog
By Richard Jefferys, Project Director at Treatment Action Group (TAG).
recent posts
- TAG’s HIV Cure-Related Clinical Research Listing: Background on the February 2026 Update
- TAG’s HIV Cure-Related Clinical Research Listing: Background on the December 2025 and January 2026 Updates
- TAG’s HIV Cure-Related Clinical Research Listing: Background on the November 2025 Update
- TAG’s HIV Cure-Related Clinical Research Listing: Background on the October 2025 Update
- TAG’s HIV Cure-Related Clinical Research Listing: Background on the September 2025 Update
Category: HDAC inhibitors
-
For September 2024 there are six updates to TAG’s listing: New Additions One new study was registered over the past month, a protocol for conducting analytical treatment interruptions (ATIs) in people with HIV who’ve received successful stem transplants to treat cancers. The criteria require that the stem cell transplants were sourced from donors homozygous for…
-
There are 14 updates in the June 2024 revision to TAG’s listing. New Additions Three newly registered studies have been added: two interventional and one observational. The German company Hookipa Biotech is sponsoring a clinical trial assessing two therapeutic HIV vaccine candidates based on an arenavirus vector platform in people with HIV on antiretroviral…
-
There are ten updates in the May 2024 revision to TAG’s listing. No new HIV cure-related clinical trials or observational studies were identified in registries this month, and one protocol was withdrawn: a combination study codenamed RV582 sponsored by the US Military HIV Research Program (MHRP). No explanation for the withdrawal is provided in the…
-
The March 2024 revision to TAG’s listing includes 26 updates. The annual Conference on Retroviruses and Opportunistic Infections (CROI) took place in Denver from March 3-6, and the addition of links to results from HIV cure-related studies presented at the meeting typically makes this the busiest month for changes — hence the delay to this…
-
There are ten updates this month: a newly entered therapeutic HIV vaccine trial in China, a new observational study in Belgium, one observational study shifted to the completed studies table, and links added to presented/published results for seven of the studies in the listing. The therapeutic HIV vaccine trial is testing a novel DNA construct…
-
The February 15, 2023 update to TAG’s HIV cure-related clinical research listing includes three newly registered studies: The AIDS Clinical Trials Group (ACTG) is initiating a study of two long-acting broadly neutralizing antibodies (bNAbs) named VRC07-523LS and PGT121.414.LS combined with antiretroviral therapy (ART) in people with acute (recently acquired) HIV infection. The trial has yet…
-
One of the most widely discussed and publicized ideas for targeting the HIV reservoir is “kick and kill” or “shock and kill.” The aim is to kick dormant, latent HIV into revealing itself so the cells that contain the virus are visible to the immune system; the kill aspect involves trying to enhance the immune…
-
The annual Conference on Retroviruses & Opportunistic Infections (CROI) took place in Seattle from February 13th-16th, offering a dizzying parade of new data. Webcasts of presentations and PDF files of posters were rapidly placed online and are accessible via the CROI website. A Fillip for Kick & Kill On the cure research front, the results…
-
The 2016 Conference on Retroviruses and Opportunistic Infections (CROI) took place in Boston from February 22-25. CROI deserves kudos for pioneering comprehensive webcasting, and all sessions are available for viewing online. Results from several significant cure-related clinical trials were debuted during the meeting (links to the webcasts are in parentheses): Ole Søgaard from Aarhus University in…
-
Several years ago, the laboratory of Robert Siliciano at Johns Hopkins University reported that the FDA-approved drug disulfiram (Antabuse) could reverse HIV latency in laboratory experiments. The discovery led Steve Deeks and colleagues to conduct a small pilot study in HIV-positive people on ART, which found that a standard dose of 500mg/day of disulfiram showed some…